Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Capital Employed (2016 - 2025)

Coherus Oncology's Return on Capital Employed history spans 12 years, with the latest figure at 0.73% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 30.0% year-over-year to 0.73%; the TTM value through Dec 2025 reached 0.73%, up 30.0%, while the annual FY2025 figure was 0.85%, 7.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.73% at Coherus Oncology, up from 1.71% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.1% in Q1 2021 and bottomed at 1.71% in Q3 2025.
  • The 5-year median for Return on Capital Employed is 0.74% (2025), against an average of 0.77%.
  • The largest YoY upside for Return on Capital Employed was 30bps in 2025 against a maximum downside of -95bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.48% in 2021, then tumbled by -41bps to 0.68% in 2022, then fell by -9bps to 0.74% in 2023, then tumbled by -39bps to 1.03% in 2024, then increased by 29bps to 0.73% in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Return on Capital Employed are 0.73% (Q4 2025), 1.71% (Q3 2025), and 1.29% (Q2 2025).